Small Lymphocytic Lymphoma (SLL)

Oncology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Bruton's tyrosine kinase inhibitorN/A1 trial
Active Trials
NCT07030400Recruiting100Est. Jun 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
AstraZenecaBruton's tyrosine kinase inhibitor

Clinical Trials (1)

Total enrollment: 100 patients across 1 trials

NCT07030400AstraZenecaBruton's tyrosine kinase inhibitor

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Start: Jul 2025Est. completion: Jun 2028100 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 100 patients
1 companies competing in this space